Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof

ABSTRACT

There are provided various compositions comprising monoglyceride(s), diglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent applicationSer. No. 16/517,607, filed on Jul. 21, 2019 that is acontinuation-in-part of International patent application no.PCT/CA2019/050139, filed on Feb. 4, 2019, which claims priority to U.S.application No. 62/627,244 filed on Feb. 7, 2018. These documents arehereby incorporated by reference in their entirety.

FIELD OF THE DISCLOSURE

The present document relates to the field of chemical biology. Moreparticularly, it relates to polyunsaturated fatty acid monoglyceridecompounds and combinations thereof. It also provides methods forincreasing the lifespan and/or slowing down the ageing process of asubject in need thereof. There is also provided a method for enhancingand/or optimizing the mitochondrial functions of a subject in needthereof by decreasing the mitochondrial proton LEAK and/or increasingthe mitochondrial OXPHOS and/or increasing the COUPLING EFFICIENCY.

BACKGROUND OF THE DISCLOSURE

The normal functions of an organism gradually decline with ageing andthe exact mechanism are not totally understood. One consensus uponalmost all specialists is that mitochondria are involved in the ageingprocess (Payne, B. A. I. and P. F. Chinnery. 2015 “Mitochondrialdysfunction in aging: Much progress but many unresolved questions.”Biochimica et Biophysica Acta 1847; 11: 1347-1353).

SUMMARY OF THE DISCLOSURE

According to one aspect there is provided at least one compound chosenfrom compound of formula (I), compound of formula (II), compound offormula (III) and compound of formula (IV):

for increasing the life span of a subject in need thereof.

According to another aspect there is provided at least one compoundchosen from compound of formula (I), compound of formula (II), compoundof formula (III) and compound of formula (IV) for increasing of thedisability-free life expectancy of a subject in need thereof.

According to another aspect there is provided at least one compoundchosen from compound of formula (I), compound of formula (II), compoundof formula (III) and compound of formula (IV) for slowing down theageing process of a subject in need thereof.

According to another aspect there is provided at least one compoundchosen from compound of formula (I), compound of formula (II), compoundof formula (III) and compound of formula (IV) for increasing themitochondrial OXPHOS of a subject in need thereof.

According to another aspect there is provided at least one compoundchosen from compound of formula (I), compound of formula (II), compoundof formula (III) and compound of formula (IV) for decreasing themitochondrial LEAK of a subject in need thereof.

According to another aspect there is provided at least one compoundchosen from compound of formula (I), compound of formula (II), compoundof formula (III) and compound of formula (IV) for increasing themitochondrial RCR or COUPLING EFFICIENCY of a subject in need thereof.

According to another aspect there is provided at least one compoundchosen from compound of formula (I), compound of formula (II), compoundof formula (III) and compound of formula (IV) for optimizing themitochondrial functions of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) for increasingthe life span of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) for increasing ofthe disability-free life expectancy of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) for slowing downthe ageing process of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) for increasingthe mitochondrial OXPHOS of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) for decreasingthe mitochondrial LEAK of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) for increasingthe mitochondrial RCR or COUPLING EFFICIENCY of a subject in needthereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) for optimizingthe mitochondrial functions of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) in themanufacture of a medicament for increasing the life span of a subject inneed thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) in themanufacture of a medicament for increasing of the disability-free lifeexpectancy of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) in themanufacture of a medicament for slowing down the ageing process of asubject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) in themanufacture of a medicament for increasing the mitochondrial OXPHOS of asubject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) in themanufacture of a medicament for decreasing the mitochondrial LEAK of asubject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) in themanufacture of a medicament for increasing the mitochondrial RCR orCOUPLING EFFICIENCY of a subject in need thereof.

According to another aspect there is provided the use of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV) in themanufacture of a medicament for optimizing the mitochondrial functionsof a subject in need thereof.

According to another aspect there is provided a method for increasingthe life span of a subject in need thereof comprising administering aneffective amount of at least one compound chosen from compound offormula (I), compound of formula (II), compound of formula (III) andcompound of formula (IV).

According to another aspect there is provided a method for increasing ofthe disability-free life expectancy of a subject in need thereofcomprising administering to the subject an effective amount of at leastone compound chosen from compound of formula (I), compound of formula(II), compound of formula (III) and compound of formula (IV).

According to another aspect there is provided a method for slowing downthe ageing process of a subject in need thereof comprising administeringto the subject an effective amount of at least one compound chosen fromcompound of formula (I), compound of formula (II), compound of formula(III) and compound of formula (IV).

According to another aspect there is provided a method for increasingthe mitochondrial OXPHOS of a subject in need thereof comprisingadministering to the subject an effective amount of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV).

According to another aspect there is provided a method for decreasingthe mitochondrial LEAK of a subject in need thereof of a subject in needthereof comprising administering to the subject an effective amount ofat least one compound chosen from compound of formula (I), compound offormula (II), compound of formula (III) and compound of formula (IV).

According to another aspect there is provided a method for increasingthe mitochondrial RCR or COUPLING EFFICIENCY of a subject in needthereof comprising administering to the subject an effective amount ofat least one compound chosen from compound of formula (I), compound offormula (II), compound of formula (III) and compound of formula (IV).

According to another aspect there is provided a method for optimizingthe mitochondrial functions of a subject in need thereof comprisingadministering to the subject an effective amount of at least onecompound chosen from compound of formula (I), compound of formula (II),compound of formula (III) and compound of formula (IV).

According to another aspect, there is provided a composition comprising:

(i) at least one compound chosen from compound of formula (I), compoundof formula (II), compound of formula (III) and compound of formula (IV);

(ii) at least one ingredient chosen from lipids, a C₁₀ saturated richoils, selenium, vitamin B and cannabinoids.

According to another aspect, there is provided a composition comprising(i) at least one compound chosen from compound of formula (I), compoundof formula (II), compound of formula (III) and compound of formula (IV)at compounds and (ii) at least one of a lipid and C₁₀ saturated rich oilfor increasing the life span or the disability-free life expectancy of asubject in need thereof

According to another aspect, there is provided a composition comprising(i) at least one compound chosen from compound of formula (I), compoundof formula (II), compound of formula (III) and compound of formula (IV)at compounds and (ii) at least one of a lipid and selenium forincreasing the life span or the disability-free life expectancy of asubject in need thereof.

According to another aspect, there is provided a composition comprising(i) at least one compound chosen from compound of formula (I), compoundof formula (II), compound of formula (III) and compound of formula (IV)at compounds and (ii) at least one a lipid and vitamin B for increasingthe life span or the disability-free life expectancy of a subject inneed thereof.

According to another aspect, there is provided a composition comprising(i) at least one compound chosen from compound of formula (I), compoundof formula (II), compound of formula (III) and compound of formula (IV)at compounds and (ii) at least one of a lipid and a cannabinoid forincreasing the life span or the disability-free life expectancy of asubject in need thereof.

BRIEF DESCRIPTION OF THE FIGURES

Further features and advantages will become more readily apparent fromthe following description of specific embodiments as illustrated by wayof examples in the appended figures wherein:

FIG. 1 represents the survival curve of Drosophila melanogaster malesfed a standard diet (SD), a standard diet supplemented with composition1, and a standard diet supplemented with composition 2. Results arepresented as the percentage of Drosophila alive counted every 2-3 days(N>145 for each group).

FIG. 2 represents the effects of composition 1 and composition 2 onmass-specific mitochondrial LEAK of thorax muscle from Drosophilamelanogaster at day 45.

FIG. 3 represents the effects of composition 1 and composition 2 onmass-specific mitochondrial OXPHOS of thorax muscle from Drosophilamelanogaster at day 45.

FIG. 4 represents the effects of composition 1 and composition 2 onmass-specific mitochondrial COUPLING EFFICIENCY of thorax muscle fromDrosophila melanogaster at day 45.

FIG. 5 represents the variation of the LEAK of the PBMC at T=0 and T=60days.

FIG. 6 represents the variation of the OXPHOS of the PBMC at T=0 andT=60 days.

FIG. 7 represents the variation of the COUPLING EFFICIENCY of the PBMCat T=0 and T=60 days.

FIG. 8 represents the variation of the LEAK of the PBMC at T=0 and T=60days.

FIG. 9 represents the variation of the OXPHOS of the PBMC at T=0 andT=60 days.

FIG. 10 represents the variation of the COUPLING EFFICIENCY of the PBMCat T=0 and T=60 days.

FIG. 11 shows the superiority of the compound of formula (IV) over theMCT oil on the absorption and bioavailability of CBD.

FIG. 12 shows the absorption and bioavailability profile of CBDA inplasma.

FIG. 13 shows the absorption and bioavailability profile of THCA inplasma.

DETAILED DESCRIPTION OF THE DISCLOSURE

Further features and advantages of the previously-mentioned compoundswill become more readily apparent from the following description ofnon-limiting examples.

The term “OXPHOS” as used herein refers to oxidative phosphorylationthat is the metabolic pathway in which cells use enzymes to oxidizenutrients, thereby releasing energy which is used to produce adenosinetriphosphate (ATP).

The term “LEAK” as used herein refers to a leak of protons that occursacross the mitochondrial inner membranes of eukaryotic cells.

The term “RCR” or “COUPLING EFFICIENCY” or “RESPIRATORY ACCEPTOR CONTROLRATIO” as used herein refers to a value calculated by OXPHOS/LEAK orstate 3/state 4.

The term “lipid” as used herein refers to as any fat-soluble(lipophilic), molecules, such as fats, fat-like substances, oils (suchas animal oil, marine oil or vegetable oil), waxes, sterols (such ascholesterol, ergosterol, sitosterol, stigmasterol, fat-soluble vitamins(such as vitamins A, D, E and K), fatty acids, oxidized fatty acid (suchas lipoxin, specialized pro-resolving mediators or epoxydes), fattyacids esters thereof, and various derivatives thereof such asmonoglycerides, diglycerides, triglycerides, phospholipids, glycolipids,and cerebrosides and pharmaceutically acceptable salts thereof.

The term “selenium” as used herein refers to mineral form such asselenates, selenides, selenites or selenocyanate or organoselenium formsuch as selenols, selenonic acid, seleno amino acids or selenoproteins.

The term “vitamin B” as used herein refers to vitamin B1 (thiamine),vitamin B2 (riboflavin), vitamin B3 (niacin or nicotinamide riboside,vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine, pyridoxal,pyridoxamine), vitamin B7 (biotin), vitamin B9 (folate) or vitamin B12(cobalamins).

The term “cannabinoids” as used herein refers to THC(Tetrahydrocannabinol), THCA (Tetrahydrocannabinolic acid), CBD(Cannabidiol), CBDA (Cannabidiolic Acid), CBN (Cannabinol), CBG(Cannabigerol), CBC (Cannabichromene), CBL (Cannabicyclol), CBV(Cannabivarin), THCV (Tetrahydrocannabivarin), CBDV, (Cannabidivarin),CBCV (Cannabichromevarin), CBGV (Cannabigerovarin), CBGM, (CannabigerolMonomethyl Ether), CBE (Cannabielsoin) or CBT (Cannabicitran).

The expression “life span” as used herein refers to Maximum life span(the maximum lifespan observed in a group), the Life expectancy (theaverage lifespan expected of a group) or the Longevity, (the averagelifespan expected under ideal conditions).

The expression “disability-free life expectancy” as used herein refersto the Healthy Life Years (HLY) indicator (also called disability-freelife expectancy) that measures the number of remaining years that aperson of a certain age is still supposed to live without disability.

The expression “effective amount” of a compound of the presentdisclosure is a quantity sufficient to, when administered to thesubject, including a mammal, for example a human, effect beneficial ordesired results, including clinical results, and, as such, an “effectiveamount” depends upon the context in which it is being applied. Theamount of a given compound of the present disclosure that willcorrespond to such an amount will vary depending upon various factors,such as the given drug or compound, the pharmaceutical formulation, theroute of administration, the identity of the subject or host beingtreated, and the like, but can nevertheless be routinely determined byone skilled in the art.

For example, the subject in need thereof can be a bee, human, cat, dog,etc. . . .

For example, the at least one compound is said compound of formula (I).

For example, the at least one compound is said compound of formula (II).

For example, the at least one compound is said compound of formula(III).

For example, the at least one compound is said compound of formula (IV).

For example, the at least one compound is said compound of formula (I),said compound of formula (III) and said compound of formula (IV).

For example, the at least one compound is said compound of formula (I)and said compound of formula (IV).

For example, the at least one compound is said compound of formula (I)and said compound of formula (III).

For example, the at least one compound is said compound of formula (III)and said compound of formula (IV).

For example, the at least one compound can be for use in combinationwith at least one ingredient chosen from lipids, a C₁₀ saturated richoils, selenium, vitamin B and cannabinoids.

For example, the at least one ingredient and said at least one compoundcan be for simultaneous administration.

For example, the at least one ingredient and said at least one compoundcan be for separate administration.

For example, the at least one compound chosen from compound of formula(I), compound of formula (II), compound of formula (III) and compound offormula (IV) can be administered in combination with at least oneingredient chosen from lipids, a C₁₀ saturated rich oils, selenium,vitamin B and cannabinoids.

For example, the at least one ingredient and said at least one compoundcan be administered simultaneously.

For example, the at least one ingredient and said at least one compoundcan be administered separately.

Further features and advantages of the previously-mentioned compoundswill become more readily apparent from the following description ofnon-limiting examples.

EXAMPLE 1

Preparation of a Composition (Composition 1) Comprising Compound III.

Composition 1 comprising compound IV, was prepared by reacting 1 kg ofEPA concentrated fish oil (ethyl ester form) with 0.27 kg of glycerolwith 0.05 kg of Novozym 435 (lipase) in 2 kg of acetone at 50° C. for 4h. The lipase was filtered, the acetone was removed in vacuo and themixture was allowed to stand for phase separation. The lower unreactedglycerol phase was removed to give 1 kg of the final composition 1comprising compound IV, unreacted ethyl ester and small amount ofdiglycerides and triglyceride.

EXAMPLE 2

Preparation of a Composition (Composition 2) Comprising Compound II.

Composition 2 comprising compound III, was prepared by reacting 1 kg ofDHA concentrated fish oil (ethyl ester form) with 0.27 kg of glycerolwith 0.05 kg of Novozym 435 (lipase) in 2 kg of acetone at 50° C. for 4h. The lipase was filtered, the acetone was removed in vacuo and themixture was allowed to stand for phase separation. The lower unreactedglycerol phase was removed to give 1 kg of the final composition 2comprising compound III, unreacted ethyl ester and small amount ofdiglycerides and triglyceride.

EXAMPLE 3

Composition 1 and Composition 2 Extend Longevity in D. Melanogaster byDecreasing the LEAK, Increasing the OXPHOS and Increasing

Coupling Efficiency

Male Drosophila (strain w1118, Bloomington Drosophila Stock Center,Bloomington, Ind., USA) were collected on the day of hatching and werefed a standard cornmeal diet (SD), or a SD supplemented with 0.3 mg·mL-1of a formulation containing composition 1 or composition 2. Thelongevity is presented in FIG. 1 and was evaluated by recording thesurvival of flies every 2-3 days (N>145, in triplicates). The threegroups were significantly different from each other (log-rank χ2=16.5,P<0.001 between SD and composition 2; log-rank χ2=48.3, P<0.001 betweenSD and composition 1; log-rank χ2=9.8, P=0.002 between composition 2 andcomposition 1). Specifically, median lifespans were similar betweencomposition 2 and composition 1 (55 days) and both were higher than whenthe flies were fed the SD (48 days). Maximal lifespan was however thehighest with composition 1 (79 days), followed by composition 2 (73days) and SD (68.5 days). Mitochondrial oxygen consumption was evaluatedin permeabilized thorax of Drosophila at 45 days old, N=5-6 for eachdietary treatment. LEAK of Drosophila fed either composition 1 orcomposition 2 were lower than with the SD, FIG. 2. Moreover, flies fedcomposition 1 presented higher OXPHOS than SD FIG. 3.

Both composition 1 and composition 2 also had higher COUPLING EFFICIENCYthan SD, and composition 1 presented higher COUPLING EFFICIENCY thancomposition 2 FIG. 4)

EXAMPLE 4

Composition 1 Decreases Mitochondrial Proton Leak, Increase the OXPHOSand Ameliorate the COUPLING EFFICIENCY in a Pilot Human Clinical Trial.

Four patients were recruited at SCF Pharma and the study was approved bya review boards. Prior to participation, all subjects signed a writteninformed consent form previously reviewed and discussed with a studyinvestigator. Eligible subjects received composition 1 (1.5 g) for 60days. The mean LEAK of the PBMC cells of the patients at T=0 (3.04) andT=60 days (1.21) is presented in FIG. 5, the mean OXPHOS of the PBMCcells of the patients at T=0 (11.24) and T=60 days (12.03) is presentedin FIG. 6, and the mean COUPLING EFFICIENCY of the PBMC cells of thepatients at T=0 (3.89) and T=60 days (9.86) is presented in FIG. 7

While the compounds, compositions, methods and uses thereof have beendescribed in connection with specific embodiments thereof, it will beunderstood that they can be further modified and this application isintended to cover any variations, uses, or adaptations of the compounds,compositions, methods and uses thereof following, in general, theprinciples described in the present document and including suchdepartures from the present disclosure as come within known or customarypractice within the art to which the present document pertains and asmay be applied to the features hereinbefore set forth, and as follows inthe scope of the appended claims.

EXAMPLE 5

Composition 1 Decreases Mitochondrial Proton Leak, Increase the OXPHOSand Ameliorate the COUPLING EFFICIENCY in a Second Pilot Human ClinicalTrial.

Six patients were recruited at SCF Pharma and the study was approved bya review boards. Prior to participation, all subjects signed a writteninformed consent form previously reviewed and discussed with a studyinvestigator. Eligible subjects received composition 1 (1.5 g) for 60days. The mean LEAK of the PBMC cells of the patients at T=0 (3.76) andT=60 days (2.04) is presented in FIG. 8, the mean OXPHOS of the PBMCcells of the patients at T=0 (10.24) and T=60 days (12.40) is presentedin FIG. 9, and the mean COUPLING EFFICIENCY of the PBMC cells of thepatients at T=0 (3.42) and T=60 days (6.89) is presented in FIG. 10.

EXAMPLE 6

54 mg of cannabidiol (CBD) was dissolved in 2.5 g of compound of formula(IV) to give a clear solution. 1.16 g of the mixture (25 mg CBD) wasencapsulated in two (2) hard gel capsules (size 00) for absorptionstudy. A pilot absorption study was conducted in one volunteer. The two(2) hard gel capsules were swallowed with a glass of water by thevolunteer fasted for 10 h. 200 ul of blood was collected by a lancet ina heparinised microtube at T=0, 1, 2, 3, 4, 5, 6, 7 and 8 h. The plasmawas analyzed by HPLC/MS/MS to quantify the CBD. A comparative study wasconducted with the same amount of CBD but with MCT oil (medium-chaintriglycerides oil) instead of compound of formula (IV). FIG. 11 showsthe superiority of the compound of formula (IV) over the MCT oil on theabsorption and bioavailability of CBD.

EXAMPLE 7

166 mg of cannabidiolic acid (CBDA) crude extract containing 20% CBDAwas dissolved in 1.33 g of compound of formula (IV) to give a clearsolution. 1.00 g of the mixture (25 mg CBDA) was encapsulated in two (2)hard gel capsules (size 00) for absorption study. A pilot absorptionstudy was conducted in one volunteer. The two (2) hard gel capsules wereswallowed with a glass of water by the volunteer fasted for 10 h. 200 ulof blood was collected by a lancet in a heparinised microtube at T=0, 1,2, 3, 4, 5, 6, 7 and 8 h. The plasma was analyzed by HPLC/MS/MS toquantify the CBDA. FIG. 12 shows the absorption and bioavailabilityprofile of CBDA in plasma.

EXAMPLE 8

106 mg of tetrahydrocannabinolic acid (THCA) crude extract containing20% THCA was dissolved in 4.00 g of compound of formula (IV) to give aclear solution. 1.00 g of the mixture (5 mg THCA) was encapsulated intwo (2) hard gel capsules (size 00) for absorption study. A pilotabsorption study was conducted in one volunteer. The two (2) hard gelcapsules were swallowed with a glass of water by the volunteer fastedfor 10 h. 200 ul of blood was collected by a lancet in a heparinisedmicrotube at T=0, 1, 2, 3, 4, 5, 6, 7 and 8 h. The plasma was analyzedby HPLC/MS/MS to quantify the THCA (the calibration curve was made withCBDA). FIG. 13 shows the absorption and bioavailability profile of THCAin plasma.

While the compounds, compositions, methods and uses thereof have beendescribed in connection with specific embodiments thereof, it will beunderstood that they can be further modified and this application isintended to cover any variations, uses, or adaptations of the compounds,compositions, methods and uses thereof following, in general, theprinciples described in the present document and including suchdepartures from the present disclosure as come within known or customarypractice within the art to which the present document pertains and asmay be applied to the features hereinbefore set forth, and as follows inthe scope of the appended claims.

What is claimed is:
 1. A composition consisting essentially of syntheticSN1 monoglyceride of fish oil, a synthetic diglyceride of fish oilselected from the group consisting of SN 1,2 synthetic diglyceride andSN 1,3 synthetic diglyceride, isolated cannabidiol, synthetic ethylester of fish oil and glycerol.